biotech · Metastatic Non-Small Cell Lung Cancer · NSCLC · AVBP
ArriVent BioPharma
ArriVent BioPharma clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Newtown Square, USA
- Employees
- 75
- Programs
- 7
- Drugs
- 4
- Patents
- 0
ArriVent BioPharma projects
7 ClinicalTrials.gov programs sponsored by ArriVent BioPharma.
ArriVent BioPharma has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
FURMO-006
ArriVent BioPharma
Advanced or Metastatic Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
1 trial -
Firmonertinib
ArriVent BioPharma
NSCLC
1 trial -
Firmonertinib
ArriVent BioPharma
Non-Small-Cell Lung Cancer
1 trial -
furmonertinib 240 mg oral, daily
ArriVent BioPharma
Metastatic Non-Small Cell Lung Cancer
1 trial -
FURMO-002
ArriVent BioPharma
Non-Small Cell Lung Cancer (NSCLC) harboring activating EGFR or HER2 kinase domain mutations
1 trial -
Furmonertinib
ArriVent BioPharma
Non-Small Cell Lung Cancer (NSCLC)
1 trial -
MRG007
ArriVent BioPharma
Locally Advanced or Metastatic Solid Tumors
1 trial
Frequently asked questions
How many clinical projects does ArriVent BioPharma have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.